Horizon Pharma (HZNP) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
Go back to Horizon Pharma (HZNP) Tops Q4 EPS by 1c
March 1, 2016 8:37 AM EST
Piper Jaffray analyst, David Amsellem, thinks that Horizon Pharma (NASDAQ: HZNP) is being painted with the same brush as Valeant and with shares trading at a 7x PE, he sees substantial value. The analyst reduced his PT to $44 from $46 but reiterated his Overweight rating.
Horizon reported 4Q15 adjusted EPS of $0.63 on... More
March 1, 2016 7:01 AM EST
Mizuho Securities maintained a Buy rating on Horizon Pharma (NASDAQ: HZNP), and cut the price target to $34.00 (from $36.00), following the company's 4Q earnings report. HZNP reported a strong revenues of $244.5M and EPS of $0.63 vs. consensus estimates of $240.8M and $0.61. Mgmt indicated the... More
February 29, 2016 3:37 PM EST
Piper Jaffray maintained an Overweight rating on Horizon Pharma (NASDAQ: HZNP), and cut the price target to $44.00 (from $46.00), following the company's 4Q earnings report. Horizon reported adjusted EPS of $0.63 on revenues of $245M, coming in ahead of Street estimates. Sales from the primary care business grew 10% sequentially in 4Q15 over 3Q15, with management citing... More
